Introduction
For many years, the techniques available for the detection of antibody on platelets were either unreliable or difficult to perform. At present, there are two general methods in use for the detection ofplatelet-bound IgG: antiglobulin consumption tests or direct labeled anti-IgG binding tests. Antiglobulin consumption tests are usually based on the principle that IgG affixed to platelets will adsorb proportionate amounts of anti-IgG from solution. The stoichiometry is assumed to be the same for platelet-bound IgG as for fluid-phase IgG and the tests are therefore calibrated by assessing the consumption of anti-IgG by known amounts of fluid-phase IgG. By these techniques, 5,000-20,000 molecules of IgG are detected on the platelets of normal donors and values >300,000 molecules/platelet have been reported in patients with idiopathic thrombocytopenic purpura (1) (2) (3) (4) (5) (6) . In addition, increased amounts of platelet-bound IgG have been found by these techniques on the platelets of thrombocytopenic patients with systemic lupus erythematosus, myeloproliferative disorders, sepsis and other infections, drug-induced purpura, various hematologic disorders, and cancer (7) (8) (9) .
Techniques that directly measure the binding of labeled anti-IgG to IgG affixed to platelets are theoretically simple to perform and to interpret (10) (11) (12) (13) . Radiolabeled ligands have been fixed to platelet-bound IgG, but when heterologous antiIgG was used as whole serum or as the IgG fraction of serum of immunized animals, the amount of IgG bound to normal platelets was often great (10) . Furthermore, it has been difficult to establish the stoichiometry between the amount of IgG on the platelet and the amount of anti-IgG bound (1 1) .
With the advent of hybridoma-derived monoclonal antiIgG antibodies which react with a single epitope of the IgG molecule, many of the objections to previous ligand-binding assays may be overcome. Using such a test, we have found that there is little binding to normal platelets (500-1,000 molecules/ platelet for monoclonal antibody, 2,000-3,000 for polyclonal antibody). The amount bound to the platelets of patients with idiopathic thrombocytopenic purpura is usually greater (2,000-50,000 molecules/platelet) but is very much less than that estimated by using a quantitative antiglobulin test with calibration curve (Rosse, W. F., and D. V. Devine, manuscript in preparation).
In the present study, we analyzed and detailed the interaction between radiolabeled monoclonal or polyclonal anti-IgG and IgG bound to platelets. We compared the results of such assays with the results of an antiglobulin consumption test by using the monoclonal antibody with and without a calibration curve using known amounts of IgG. When a calibration curve in which IgG in fluid phase or bound to plastic or surfaces other than the platelet membrane is used to estimate the amount of anti-IgG consumed, falsely high values for the amount of IgG bound to the platelet are derived. When the amount of antiIgG consumed is estimated either directly (by loss of radioactivity) or by calibration with known amounts of IgG affixed to platelets, the binding of IgG is the same as that detected using direct anti-IgG binding. This suggests that the discrepancy noted between antiglobulin consumption tests and direct binding assays is due to differences in the binding of anti-IgG when bound to IgG on the platelet surface compared with its binding to IgG affixed to other surfaces or in fluid phase.
Methods

Ligands
Monoclonal antibody. Monoclonal mouse antibody known to be specific for the Fc portion of human IgG (Bethesda Research Laboratories, Gaithersburg, MD) was purified from ascites fluid by two methods. I and 1.5 ml of ascites fluid was either dialyzed against 0.02 M KH2PO4, pH 8.0, 0.02% sodium azide, then passed over a 10-ml column of DEAE AffiGel Blue (Bio-Rad Laboratories, Richmond, CA) equilibrated in the same buffer or passed over a 3-ml column of AffiGel Blue (Bio-Rad Laboratories) in phosphate-buffered saline (PBS), pH 7.4, without prior dialysis. The fall-through protein from either method was then concentrated and dialyzed against PBS, pH 7.4, containing 5 mM benzamidine (Sigma Chemical Co., St. Louis, MO), 5 mM epsilon aminocaproic acid (Sigma Chemical Co.), and 0.02% sodium azide (Sigma Chemical Co.) prior to chromatography on Sephadex G-200. Fractions were pooled and purity was determined by polyacrylamide gel electrophoresis (PAGE). The purified antibody contained minor (<5%) contamination with other proteins by sodium dodecyl sulfate-PAGE. The antibody was preserved 1. Abbreviations used in this paper: PAGE, polyacrylamide gel electrophoresis.
in frozen fractions which were thawed for use. F(ab')2 fragments were prepared by pepsin digestion of purified monoclonal antibody (14 The data were analyzed in three ways: (a) The quantity of ligand bound to the platelet was plotted against a concentration of ligand used in the mixture (Figs. 1  and 2, A) . By this analysis, the amount of ligand bound to normal unsensitized platelets was directly proportional to the concentration of ligand used in the reaction mixture; the doseresponse curves were nearly linear at all concentrations tested, particularly for monoclonal anti-IgG. The amount ofpolyclonal anti-IgG bound for a given concentration of ligand was greater than for monoclonal anti-IgG.
The net binding to IgG-coated platelets (the total amount of ligand bound less the amount bound to normal platelets) reached a maximum value when 50-75 gg/ml of each ligand was used and was, at higher concentrations, nearly the same as this maximum.
(b) To determine whether sufficient ligand was used to estimate maximal binding, the data were plotted according to the method of Klotz (21) (21); the log of the molar concentration in fluid phase is shown on the abscissa. F, free.
plotted against the number of molecules bound to each platelet ( Figs. 1 and 2, B) . With both monoclonal and polyclonal antiIgG, a symmetric sigmoid curve was obtained, indicating that sufficient ligand was present to measure binding. The inflection point of this curve occurs at the point where half of the sites are bound.
(c) According to the method of Scatchard (22), the amount of radiolabeled ligand bound per platelet was plotted against the amount bound divided by the amount remaining in fluid phase at equilibrium expressed in moles per liter (Fig. 3) . The line, when apparently straight, was analyzed by the least squares method. By such analysis, the intercept with the abscissa indicates the maximum number of binding sites available to the ligand; the ratio of predicted sites to sites measured by '3'I-IgG (varying between 10,000-50,000 molecules/cell) was calculated. The slope ofthe line was measured and the apparent dissociation constant (KD) for the reaction was calculated as the reciprocal of the slope of the line (Table I) . In some instances, a line curvilinear to the origin was obtained. The assumption was made that the curvilinearity was due to heterogeneity of binding constants in the interaction and the simplest analysis was made; i.e., that reactions with two binding constants were being measured. The curves were then analyzed by a curve subtraction method.
Monoclonal anti-IgG. When monomeric IgG was used to sensitize platelets, monoclonal anti-IgG gave linear curves on Scatchard analysis. The affinity was high and the proportion of anti-IgG binding sites indicated by this analysis was consistently -2/3 of that indicated when the 131I-labeled IgG fraction from serum containing alloimmune anti-PlAl or autoimmune antibody was used to sensitize the platelets (Table I ). The proportion of sites detected remained constant over the fivefold difference in site number in these experiments. Assays performed in the absence of EDTA and gelatin gave entirely similar results (data not shown).
When artificially produced and chromatographically defined aggregates of IgG or serum or serum fractions containing immune complexes were used to coat the platelets and the binding was analyzed by the method of Scatchard, a curvilinear line resulted. These curves were analyzed as though the curvature resulted from the presence of binding sites with two different affinities; the affinity of the majority of the sites corresponded to the affinity of monomeric IgG with the monoclonal anti-IgG (Fig. 4) .
Polyclonal anti-IgG. When the binding of the polyclonal, heterologous, affinity-purified anti-IgG was analyzed by the Scatchard method, a straight line was obtained (Fig. 3) . The KD was greater than for monoclonal and the ratio of sites predicted by the Scatchard analysis to the number determined by 1311. labeled IgG was >1 (Table I ). The curve obtained upon plotting according to the method of Klotz indicated that sufficient antibody was used to validate this extrapolation (Fig. 2 B) . (Table II) .
When platelets sensitized with the IgG fraction ofantiserum containing anti-PI"A were substituted in the experiments de- (Table III) .
When sensitized platelets were used in such experiments, the binding of radiolabeled ligand was markedly reduced compared with that observed with unsensitized platelets.
Binding ofF(ab)2 fragments of monoclonal anti-IgG To determine whether the "nonspecific" binding required the Fc portion of the monoclonal antibody molecules, F(ab')2 fragments ofthe antibody were reacted with platelets sensitized with anti-PlAl serum and with autologous serum. Approximately the same number of F(ab')2 fragments were affixed as were IgG antibody molecules (Table IV) .
Detection ofplatelet-bound IgG by antiglobulin consumption The reduction in the amount ofmonoclonal anti-IgG remaining after incubation with known amounts of IgG in fluid phase, (1) .
Discussion
In order for a radiolabeled ligand to be used in the detection of platelet-bound IgG, the characteristics of the reaction of the ligand with the "receptor" (platelet-bound IgG) and with the platelet itself must be carefully analyzed. The stoichiometry of the specific reaction can be determined from such studies of the nature of the binding.
When radiolabeled ligands are reacted with washed normal platelets, ligand is bound. The amount varies with the ligand and is greater with polyclonal anti-IgG and less with monoclonal anti-IgG. The binding could be to IgG bound to the platelet but not removed on washing (specific binding) or to the platelet directly (nonspecific binding); previous studies have suggested that IgG is present in small amounts on the surface of the normal, washed platelet (23) .
The present studies suggest that much ofthe binding ofantiIgG to washed normal platelets is nonspecific since the inter- in which the amount of antiglobulin consumed is measured directly without reference to a calibration curve, very much less IgG is measured; the amount detected in these assays was similar to the amount detected by direct radioligand assays. Thus, from these studies, it is apparent that the radiolabeled monoclonal anti-IgG assay most accurately measured the amount of IgG on the platelet surface. A direct antiglobulin consumption assay which measured the consumption of radiolabeled ligand without reference to a calibration curve was equally accurate. However, any assay which relies upon a calibration curve to measure the consumption of antiglobulin in which the IgG used to calibrate the assay is not attached to platelets will vastly overestimate the amount of IgG present on the platelet surface.
